Unicycive Therapeutics, Inc. (UNCY) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
7.09
↑+64% vs avg
5yr avg: 4.31
30Y Low1.5·High7.2
ROE
↓
-2028.1%
↑-154% vs avg
5yr avg: -799.5%
30Y Low-225%·High-145%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
UNCY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Unicycive Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $53M | $53M | $21M | $8M | $24M | — | — | — |
| Enterprise Value | $27M | $28M | $12M | $8M | $8M | — | — | — |
| P/E Ratio → | -1.40 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 31.56 | 8.55 | — | — | — | — |
| P/B Ratio | 7.09 | 7.16 | — | — | 1.46 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
UNCY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 18.39 | 8.28 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
UNCY Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -1898.2% to -3077.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -2028.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | — | — | -3077.6% | -1898.2% | — | — | — | — |
| Net Profit Margin | — | — | -4525.0% | -1898.8% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -2028.1% | -2028.1% | — | -225.5% | -145.0% | — | — | — |
| ROA | -160.2% | -160.2% | -359.2% | -167.5% | -105.7% | -2249.3% | -9600.0% | -3862.1% |
| ROIC | — | — | — | — | -16223.5% | — | — | — |
| ROCE | -1527.6% | -1527.6% | — | -223.2% | -128.5% | — | — | — |
UNCY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $26M exceeds total debt of $773000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | — | — | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -3.41 | — | — | -0.99 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -452.35 | -452.35 | -253.34 | -3008.67 | -14.29 | -8.28 | -14.12 | — |
Net cash position: cash ($26M) exceeds total debt ($773000)
UNCY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.28x means Unicycive Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.81x to 1.28x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Quick Ratio | 1.28 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Cash Ratio | 1.08 | 1.08 | 0.55 | 0.14 | 7.88 | — | 0.02 | 0.02 |
| Asset Turnover | — | — | 0.05 | 0.34 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
UNCY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Unicycive Therapeutics, Inc. returns 2.1% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.1% | 2.1% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 2.1% | 2.1% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $2M | $2M | $1M | $2M | $847146 | $794322 |
Peer Comparison
Compare UNCY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 UNCYYou | $53M | -1.4 | — | — | — | — | -2028.1% | — | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 CYCN | $14M | -2.9 | — | — | 100.0% | -239.8% | -39.3% | -65.1% | — |
 RMTI | $31M | -5.2 | — | — | 16.9% | -6.8% | -15.3% | -11.0% | — |
 LPCN | $13M | -1.4 | — | — | -334.3% | -524.7% | -54.3% | -64.7% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 VKTX | $4B | -9.9 | — | — | — | — | -47.3% | -44.4% | — |
 DVAX | $2B | 77.5 | 503.2 | 30.2 | 82.2% | -1.5% | 4.5% | -0.4% | 64.7 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See UNCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UNCY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare UNCY vs ARWR
Side-by-side business, growth, and profitability comparison vs Arrowhead Pharmaceuticals, Inc..
Start ComparisonUNCY — Frequently Asked Questions
Quick answers to the most common questions about buying UNCY stock.
What is Unicycive Therapeutics, Inc.'s P/E ratio?
Unicycive Therapeutics, Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
What is Unicycive Therapeutics, Inc.'s ROE?
Unicycive Therapeutics, Inc.'s return on equity (ROE) is -2028.1%. The historical average is -185.3%.
Is UNCY stock overvalued?
Based on historical data, Unicycive Therapeutics, Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Unicycive Therapeutics, Inc.'s dividend yield?
Unicycive Therapeutics, Inc.'s current dividend yield is 2.08%.